Author: Verma, Henu Kumar
Title: Radiological and clinical spectrum of COVID-19: A major concern for public health Cord-id: q1lbzu5n Document date: 2021_3_28
ID: q1lbzu5n
Snippet: The pandemic of novel coronavirus disease 2019 (COVID-19) is an infectious disease caused by +ve strand RNA virus (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2) that belongs to the corona viridae family. In March, the World Health Organization declared the outbreak of novel coronavirus for the public health emergency. Although SARS-CoV-2 infection presents with respiratory symptoms, it affects other organs such as the kidneys, liver, heart and brain. Early-stage laboratory disease
Document: The pandemic of novel coronavirus disease 2019 (COVID-19) is an infectious disease caused by +ve strand RNA virus (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2) that belongs to the corona viridae family. In March, the World Health Organization declared the outbreak of novel coronavirus for the public health emergency. Although SARS-CoV-2 infection presents with respiratory symptoms, it affects other organs such as the kidneys, liver, heart and brain. Early-stage laboratory disease testing shows many false positive or negative outcomes such as less white blood cell count and a low number of lymphocyte count. However, radiological examination and diagnosis are among the main components of the diagnosis and treatment of COVID-19. In particular, for COVID-19, chest computed tomography developed vigorous initial diagnosis and disease progression assessment. However, the accuracy is limited. Although real-time reverse transcription-polymerase chain reaction is the gold standard method for the diagnosis of COVID-19, sometimes it may give false-negative results. Due to the consequences of the missing diagnosis. This resulted in a discrepancy between the two means of examination. Conversely, based on currently available evidence, we summarized the possible understanding of the various patho-physiology, radio diagnostic methods in severe COVID-19 patients. As the information on COVID-19 evolves rapidly, this review will provide vital information for scientists and clinicians to consider novel perceptions for the comprehensive knowledge of the diagnostic approaches based on current experience.
Search related documents:
Co phrase search for related documents- low specificity and lung disease: 1, 2, 3, 4, 5, 6
- low specificity and lung infection: 1, 2, 3
- low specificity and lung pneumothorax: 1
- low specificity and lung ultrasound: 1, 2
- lung damage and lus lung ultrasound: 1, 2, 3, 4, 5, 6
- lung damage and magnetic resonance: 1
- lung disease and lus lung ultrasound: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- lung disease and lymphocytopenia wbc count: 1
- lung disease and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- lung disease assessment and lus lung ultrasound: 1, 2, 3
- lung disease assessment and magnetic resonance: 1
- lung infection and lus lung ultrasound: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- lung infection and magnetic resonance: 1, 2
- lung pneumothorax and lus lung ultrasound: 1, 2
- lung region and lus lung ultrasound: 1, 2, 3, 4
- lung ultrasound and lus integration: 1
- lung ultrasound and lus lung ultrasound: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- lung ultrasound and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- lus lung ultrasound and magnetic resonance: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date